PE38997A1 - Antagonista de taquicinina - Google Patents

Antagonista de taquicinina

Info

Publication number
PE38997A1
PE38997A1 PE1995286859A PE28685995A PE38997A1 PE 38997 A1 PE38997 A1 PE 38997A1 PE 1995286859 A PE1995286859 A PE 1995286859A PE 28685995 A PE28685995 A PE 28685995A PE 38997 A1 PE38997 A1 PE 38997A1
Authority
PE
Peru
Prior art keywords
phenyl
compound
formula
disstituted
carbamoil
Prior art date
Application number
PE1995286859A
Other languages
English (en)
Inventor
Soo Young Ko
Christopher Walpole
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9425085.9A external-priority patent/GB9425085D0/en
Priority claimed from GBGB9426016.3A external-priority patent/GB9426016D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE38997A1 publication Critical patent/PE38997A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof

Abstract

SE REFIERE AL COMPUESTO ANALGESICO Y ANTIINFLAMATORIO DE FORMULA I DONDE: R1 ES FENILO MONO O DISUSTITUIDO POR UNO O DOS MIEMBROS SELECCIONADOS DE HALOGENO, NITRO, CIANO ENTRE OTROS; n ES CERO O UNO; X1 ES OXIGENO, AZUFRE o =NCN; X2 Y X3 SON CADA UNO INDEPENDIENTEMENTE OXIGENO O AZUFRE; R2 ES HIDROGENO O METILO; R3 ES FENILO, FENILO SUSTITUIDO CON HALO, 2-NAFTILO, ENTRE OTROS; Z ES -N(CH3) o -CH2-; R4 ES FENILO, 3,5-BIS(TRIFLUOROMETIL)FENILO O PIRIDILO; R5 ES HIDROGENO, FENILO, 3,5-BIS(TRIFLUOROMETIL)FENILO O PIRIDILO; TAMBIEN SE REFIERE AL PROCESO DE PRODUCCION QUE COMPRENDE LA REACCION DEL COMPUESTO DE FORMULA II DONDE R2, R3, R4 Y R5 YA SE DEFINIERON, CON EL COMPUESTO DE FORMULA R1`-(CH2)n-N=C=X1 EN LA QUE R1' ES FENILO, MONO O DISUSTITUIDO POR UNO O DOS MIEMBROS SELECCIONADOS DEL GRUPO QUE CONSISTE DE HALOGENO, NITRO, CIANO ENTRE OTROS; n Y X1 TIENEN LOS SIGNIFICADOS YA INDICADOS; CUANDO SE REQUIERE, LLEVAR A CABO LA DESPROTECCION DEL COMPUESTO ASI OBTENIDO, EN EL QUE R1' ES FENILO SUSTITUIDO POR HIDROXI PROTEGIDO Y/O HIDROXIMETILO PROTEGIDO Y/O REALIZAR LA TRANSFORMACION DEL COMPUESTO ASI OBTENIDO, EN EL QUE R1 ES FENILO SUSTITUIDO POR METOXICARBONILO, PARA OBTENER EL COMPUESTO CORRESPONDIENTE EN EL QUE R1' ES FENILO SUSTITUIDO POR CARBAMOILO o N-METILCARBAMOILO Y LUEGO LA RECUPERACION DEL COMPUESTO
PE1995286859A 1994-12-13 1995-12-11 Antagonista de taquicinina PE38997A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9425085.9A GB9425085D0 (en) 1994-12-13 1994-12-13 Organic compounds
GBGB9426016.3A GB9426016D0 (en) 1994-12-22 1994-12-22 Organic compounds

Publications (1)

Publication Number Publication Date
PE38997A1 true PE38997A1 (es) 1997-10-02

Family

ID=26306161

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1995286859A PE38997A1 (es) 1994-12-13 1995-12-11 Antagonista de taquicinina

Country Status (17)

Country Link
EP (1) EP0797583A1 (es)
JP (1) JPH10511935A (es)
AR (1) AR001332A1 (es)
AU (1) AU4343796A (es)
BR (1) BR9509997A (es)
CA (1) CA2204130A1 (es)
CO (1) CO4700289A1 (es)
CZ (1) CZ179097A3 (es)
FI (1) FI971685A (es)
HU (1) HUT77002A (es)
IL (1) IL116323A0 (es)
NO (1) NO972526D0 (es)
PE (1) PE38997A1 (es)
PL (1) PL320217A1 (es)
SK (1) SK74697A3 (es)
TR (1) TR199501568A2 (es)
WO (1) WO1996018643A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0929303B1 (en) * 1996-10-07 2006-07-26 Merck Sharp & Dohme Ltd. Cns-penetrant nk-1 receptor antagonists as antidepressant and/or an anti-anxiety agent
US6117855A (en) * 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
KR100699404B1 (ko) 1999-02-18 2007-03-23 가켄 세야쿠 가부시키가이샤 성장 호르몬 분비촉진제로서의 신규 아미드 유도체
KR101389246B1 (ko) 2004-07-15 2014-04-24 브리스톨-마이어스스퀴브컴파니 아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및 이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
JP5258561B2 (ja) 2005-07-15 2013-08-07 アルバニー モレキュラー リサーチ， インコーポレイテッド アリール置換およびヘテロアリール置換テトラヒドロベンズアゼピンならびにノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを遮断するためのその使用
JP4879988B2 (ja) 2005-09-29 2012-02-22 メルク・シャープ・エンド・ドーム・コーポレイション メラノコルチン−４受容体モジュレーターとしてのアシル化スピロピペリジン誘導体
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2008039327A2 (en) 2006-09-22 2008-04-03 Merck & Co., Inc. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
CA2674436C (en) 2007-01-10 2012-07-17 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
CA2676357A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1
EP2145884B1 (en) 2007-04-02 2014-08-06 Msd K.K. Indoledione derivative
CA2690191C (en) 2007-06-27 2015-07-28 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
KR20100126467A (ko) 2008-03-03 2010-12-01 타이거 파마테크 티로신 키나아제 억제제
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
JP5739415B2 (ja) 2009-05-12 2015-06-24 ブリストル−マイヤーズ スクウィブ カンパニー （Ｓ）−７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンの結晶形態およびその使用
EP2429296B1 (en) 2009-05-12 2017-12-27 Albany Molecular Research, Inc. 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
MX2011011901A (es) 2009-05-12 2012-01-20 Albany Molecular Res Inc Tetrahidroisoquinolinas aril, heteroaril, y heterociclo sustituidas y uso de las mismas.
EA023838B1 (ru) 2009-10-14 2016-07-29 Мерк Шарп Энд Домэ Корп. ЗАМЕЩЕННЫЕ ПИПЕРИДИНЫ, КОТОРЫЕ ПОВЫШАЮТ АКТИВНОСТЬ p53, И ИХ ПРИМЕНЕНИЕ
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
EP3330377A1 (en) 2010-08-02 2018-06-06 Sirna Therapeutics, Inc. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
CA2807307C (en) 2010-08-17 2021-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
WO2012036997A1 (en) 2010-09-16 2012-03-22 Schering Corporation Fused pyrazole derivatives as novel erk inhibitors
EP3766975A1 (en) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
CN103732592A (zh) 2011-04-21 2014-04-16 默沙东公司 胰岛素样生长因子-1受体抑制剂
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
EP2844261B1 (en) 2012-05-02 2018-10-17 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
US9233979B2 (en) 2012-09-28 2016-01-12 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
SI2925888T1 (en) 2012-11-28 2018-02-28 Merck Sharp & Dohme Corp. Compounds and methods for the treatment of cancer
AU2013361694B2 (en) 2012-12-20 2017-10-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as HDM2 inhibitors
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164372A (en) * 1989-04-28 1992-11-17 Fujisawa Pharmaceutical Company, Ltd. Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
JPH05186498A (ja) * 1991-12-27 1993-07-27 Japan Tobacco Inc プロリン誘導体

Also Published As

Publication number Publication date
NO972526L (no) 1997-06-03
AU4343796A (en) 1996-07-03
FI971685A (fi) 1997-08-13
SK74697A3 (en) 1997-11-05
JPH10511935A (ja) 1998-11-17
FI971685A0 (fi) 1997-04-18
EP0797583A1 (en) 1997-10-01
IL116323A0 (en) 1996-03-31
CO4700289A1 (es) 1998-12-29
WO1996018643A1 (en) 1996-06-20
AR001332A1 (es) 1997-10-22
MX9703957A (es) 1997-09-30
TR199501568A2 (tr) 1996-07-21
PL320217A1 (en) 1997-09-15
NO972526D0 (no) 1997-06-03
CZ179097A3 (en) 1997-10-15
CA2204130A1 (en) 1996-06-20
BR9509997A (pt) 1997-12-30
HUT77002A (hu) 1998-03-02

Similar Documents

Publication Publication Date Title
PE38997A1 (es) Antagonista de taquicinina
PE52396A1 (es) Nuevo compuesto que puede mantener, aumentar o restaurar la sensibilidad de las celulas a los agentes terapeuticos o profilacticos
ES2059327T3 (es) Derivados de tetrahidronaftaleno y de indano, obtencion de los mismos y utilizacion en preparados farmaceuticos.
ATE89263T1 (de) Naphthalin-derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
HUP0301671A2 (hu) 4-Fenil-piridin-származékok, mint neurokinin-1-receptor antagonisták, eljárás az előállításukra és alkalmazásuk
PT1075259E (pt) Novos analogos gordos para o tratamento de diabetes
ATE524433T1 (de) Trpv1 agonisten , zubereitungen die diese enthalten und ihre anwendung
ATE240314T1 (de) Kristalle von benzimidazolderivate und verfahren zu ihrer herstellung
MX9207335A (es) Nuevos derivados del acido fosfonosuccinico, procesos para su preparacion y composicion farmaceuticas que los contiene.
DK142084D0 (da) N-phenyl-n'-cycloalkylalkanoyl-piperaziner og fremgangsmaade til fremstilling heraf
PE58599A1 (es) 2-amino-6-(4-fenoxi-2-sustituido)-piridinas sustituidas
PE120099A1 (es) Nueva 3,4-diariltiazolina-2-ona o 2-tiona derivados, sus metodos de preparacion y su uso terapeutico
DE3583872D1 (de) Dihydropyridin-derivate, verfahren zu ihrer herstellung, diese enthaltende pharmazeutische zusammensetzungen, und verfahren zur herstellung dieser zusammensetzungen.
ES8301890A1 (es) Procedimiento para la preparacion de nuevas fenilalcohilaminas .
BR9809496A (pt) Composto, processo para produzi-lo, uso do mesmo, preparação farmacêutica, e, processo para tratar pacientes necessitados de tratamento.
KR910700225A (ko) 할로 치환된 아미노테트랄린
ATE178059T1 (de) 4-phenylcarbamoyl-3-isoxazolecarbonsäure-deriva e mit entzündungshemmender aktivität
DE69618050D1 (de) Substituierte Benzylthienylpiperazine, ihre Anwendung als Arzneimittel und Verfahren für ihre Herstellung
PT76335B (de) Neue basisch substituierte 4-phenyl-4,5,6,7-tetrahydro-thieno-<2,3-c>pyridine verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
ES2145480T3 (es) Amidas de acido carbamoilcarboxilico.
DE69316392D1 (de) Azanoradamantane
DE3676378D1 (de) Isoxazolderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutischen praeparate.
KR870003082A (ko) 옥스에탄 및 티에탄 유도체의 제조방법
KR910006292A (ko) 방향족 산의 n-아자비시클로 [3.3.0] 옥탄 아미드
ES2040744T3 (es) Un procedimiento para preparar derivados de 1,2,4-triazinona.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed